MetaCap

Altimmune (ALT) vs Q32 Bio (QTTB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Q32 Bio (QTTB) has outperformed Altimmune (ALT) over the past year, gaining 317.0% versus a loss of 72.3%. Over five years, ALT leads with a -87.2% price change compared with -91.1% for QTTB. Altimmune is the larger company by market cap ($258.8 million vs $249.6 million), about 1.0 times the size.

Q32 Bio converts more of its revenue into profit, with a net margin of 55.5% versus -214861.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALT-72.35%QTTB+317.00%
+1021%+448%-124%
Nov 21, 20251 yearNov 20, 2026
ALT-87.39%QTTB-91.04%
+123%+7%-109%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALT versus QTTB key metrics
MetricALTQTTB
Share price$1.33$8.34
Market cap$258.80M$249.57M
1-day change-5.67%-1.65%
YTD return-63.16%+151.20%
1-year return-72.35%+317.00%
5-year return-87.24%-91.12%
P/E ratio (TTM)—2.32
EPS (TTM)$-0.71$3.60
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$41.00K$53.74M
Revenue growth (YoY)+105.00%—
Net income (latest FY)$-88.09M$29.82M
Operating margin-230460.98%31.45%
Net margin-214860.98%55.49%
52-week high$6.44$23.57
52-week low$1.32$1.98
Distance from 52-week high-79.35%-64.62%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+1127.82%+375.66%
Average volume3.91M692.58K
Shares outstanding194.59M29.92M
Employees5725
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • QTTB has outperformed ALT by 389.3 percentage points over the past year.
  • Q32 Bio is more profitable, keeping 55.5 cents of every revenue dollar as net income versus -214861.0 cents for Altimmune.

About Altimmune

ALT stock →

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees

About Q32 Bio

QTTB stock →

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata.

Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees

ALT vs QTTB FAQ

Which is bigger, Altimmune or Q32 Bio?

Altimmune (ALT) is larger, with a market capitalization of $258.80M compared with $249.57M for Q32 Bio (QTTB).

Which stock has performed better over the past year, ALT or QTTB?

QTTB returned +317.00% over the past 12 months, compared with -72.35% for ALT (price return, excluding dividends). Past performance does not predict future results.

Are Altimmune and Q32 Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons